Terrence Higgins Trust uses cookies to improve your experience of our websites. For more information or to change the use of cookies, please click here.

Accept and Close

Eviplera (rilpivirine + tenofovir disoproxil + emtricitabine)


Generic name: Eviplera is a combination of the drugs rilpivirine, tenofovir disoproxil and emtricitabine.

Brand names: Eviplera

Class: Complete combination tablets


Very common (affecting more than 1 in 10 people): Insomnia (difficulty sleeping), weakness, fatigue, headache, nausea, rash, low blood phosphate levels, increased creatine kinase levels in the blood that could lead to muscle pain and weakness, increase in cholesterol and/or pancreatic amylase, raised liver enzymes.

Common (may affect up to 1 in 10 people): Rashes - sometimes with swelling and blistering of the skin, depression, stomach pains, bloating, flatulence, decreased appetite, abnormal dreams, drowsiness, tiredness, pancreas problems, darkening of skin in patches, wheezing, swelling or light headedness caused by an allergic reaction, low white blood count, low platelet count, decreased haemoglobin, increased triglycerides, bilirubin or sugar in the blood.

Uncommon (may affect up to 1 in 100 people): Anaemia, swelling of the face, lips, tongue or throat, abdominal pain caused by inflammation of the pancreas, severe skin reactions which include a rash accompanied by fever, swelling and liver problems, symptoms of infection or inflammation, lowered levels of potassium in the blood, increased creatinine in the blood, changes to the urine.


Tablet comprising 25mg rilpivirine, 200mg emtricitabine and 245mg tenofovir disoproxil.

Take one tablet once a day.


Take with food.

Eviplera is licensed in the EU for those with a viral load of 100,000 copies/ml or less.

*Last reviewed on 19/12/2016 Next review: 19/12/2019

Any questions? Email feedback@tht.org.uk Information included on this website was correct at the time of publication.

Data and image supplied by NAM.

Further information on this drug from NAM